Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
16.09
+0.15 (+0.94%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
Next >
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 14, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
August 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
July 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
July 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
June 18, 2024
From
Acadia Pharmaceuticals, Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 09, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
May 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
April 29, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
April 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
April 22, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
April 02, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
March 13, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
March 11, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
February 29, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
February 27, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 21, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 13, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Announces Additions to Executive Team
January 30, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
January 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
December 21, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
December 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.